Drug Resistance Mutations In Transplant Recipients With Suspected Resistance

Abstract

Resistant CMV infections are challenging complications after SOT and HSCT. Prompt recognition of ARMs is imperative for appropriate therapy. 108 plasma samples from 96 CMV+ transplant recipients with suspected resistance were analysed in CNM in a retrospective nationwide study from January 2018 to July 2022 for resistance genotyping. ARMs in UL97 and UL54 were found in 26.87 % (18/67) and 10.60 % (7/66) of patients, respectively. Patients ARM distribution in UL97 was as follows: L595S n=3; L595S/M460I n=1; L595S/N510S n=1; L595W n=1; C603W n=4; A594V n=3; A594E n=1; C607Y n=1; L397R/T409M/H411L/M460I n=1; L397I n=1; H520Q n=1; four patients showed ARMs in UL54 as well (F412C n=1; T503I n=2; P522S n=1), whereas three patients exhibited ARMs in UL54 only (L501I/T503I/L516R/A834P n=1; A987G n=2). L516R in UL54 and L397R/I and H411L in UL97 have been found for the first time in a clinical sample. L595S/W was the most prevalent ARM found to lend resistance to GCV. In UL54 all ARMs lent resistance to GCV and CDV. In addition, A834P, found in one patient, also lent resistance to FOS. CMV load did not differ significantly in patients with or without ARMs, and no differences were found either between patients with ARMs in UL97 or in UL97 and UL54. Despite extensive use of classical antivirals for the treatment of CMV infection after HSCT and SOT, ARMs occurred mainly in viral UL97 kinase, which suggests that CDV and mostly FOS continue to be useful alternatives to nucleoside analogues after genotypic detection of ARMs.